ELDNEledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (ELDN) sells immune-modulating therapies for kidney transplant and type 1 diabetes patients, with a focus on tegoprubart. The next catalyst is Oct 23, 2026 — Eledon Pharmaceuticals presents Phase 2 kidney transplant study results, which will test the durability of kidney function and patient-reported outcomes in the Phase 2 BESTOW trial.
- ELDN has no revenue and is cash-burning, with $81.08M in shareholders’ equity and $150.31M in TTM free cash flow outflows.
- The company is heavily reliant on clinical trial outcomes and strategic partnerships to advance its pipeline.
- The Phase 2 results are a critical proof point for the drug’s efficacy and could influence the path to pivotal trials.
The Read
7% post-Q1 2026 earnings despite clinical progress due to missing broader enrollment catalysts.
The schedule
- Wed20Jan
The initiation of the pivotal Phase 3 trial will test the company's ability to advance its therapy into a larger, more critical trial, which is a key milestone for regulatory approval and investor confidence.
- Sun14Feb
This release will test the company's ability to maintain momentum from the previous quarter, with a focus on updated guidance and progress in pivotal trials that could influence regulatory timelines.
- Tue16Feb
Q3 2026 results coupled with crucial FDA regulatory feedback regarding the pivotal Phase 3 trial design for tegoprubart, carrying a $4.10 target and $2.70 fallback.
- Tue16Feb
This event will test the company's ability to deliver encouraging top-line results from its Phase 2 trial, which could impact its valuation and attract further investment.
- Tue16Feb
Anticipated mid-Q4 update on the Type 1 Diabetes program, potentially including further collaborative milestones with NewcelX to drive shares toward $3.40 or break support at $2.30.
- Wed12May
This earnings report will be a critical test of Eledon's ability to sustain growth and deliver on its clinical and financial roadmap, with a focus on pivotal trial data and updated cash flow projections.
- Sun20Jun
The investor presentations will test the company's ability to communicate its strategy, progress, and future plans, which could influence investor sentiment and stock performance.
- Thu12Aug
The final earnings release of the year will test Eledon's ability to deliver on its long-term strategy, with a focus on regulatory milestones and potential near-term catalysts that could influence its valuation.
Past
- Thu13Aug
Actual outcome: Bear · $3.53 at outcome
Eledon reported an EPS actual of -0.35, matching the estimate, but the stock fell 4.6% from the event to outcome date. The lack of positive surprises in operating expenses or progress on the NewcelX collaboration led to a bearish reaction. The price fell below the bear floor of $2.85, reflecting investor disappointment with the lack of momentum or strategic clarity.
Eledon's Q2 print will update the Street on operating expenses and initial progress on the NewcelX collaboration, targeting a $3.90 favorable resolution or a $2.85 adverse floor.
- Thu25Jun
The presentation will test the company's ability to showcase positive Phase 2 data, which could influence investor sentiment and provide clarity on the potential of its kidney transplant therapy.
- Wed13May
Actual outcome: Bear · $3.58 at outcome
Eledon met Q1 2026 EPS estimates of -$0.14 and announced positive pipeline developments, including an FDA Orphan Drug designation for tegoprubart and successful insulin independence in 10 type 1 diabetes patients. Despite these clinical milestones and a strong cash position of $111.1 million, the stock fell 7.7% as the earnings report lacked the anticipated upside catalysts regarding broader clinical enrollment progress.
Eledon will report Q1 2026 financials and provide updates on clinical enrollment for its lead asset, tegoprubart.
- Wed15Apr
Actual outcome: Mixed · $3.34 at outcome
Eledon Pharmaceuticals announced a strategic collaboration with NewcelX for a Type 1 Diabetes flagship program shortly after its equity financing. This positive partnership development overshadowed the dilution event, driving the stock steadily higher until it exceeded the bull target.
On 2026-04-15 Eledon is expected to price a confirmed equity financing to extend its cash runway through upcoming Phase 2 readouts. At a base price of $3.13, a well-covered deal with a modest discount and quality specialist participation could support a move toward $3.50, while a deeply discounted raise or weak demand that signals funding stress could push the stock down toward $3.50 by 2026-04-29.
- Thu19Mar
Actual outcome: Bull · $2.89 at outcome
The company reported in-line EPS of -0.14, matching expectations, and provided guidance indicating stabilization in demand. The critical cash runway update signaled improved financial health, which drove the stock higher. The price surpassed the bull target, reflecting market confidence in the company's strategic direction and financial outlook.
Release of fiscal year results with a specific focus on the remaining cash runway, which was critically low in previous filings.